About Company
- Legal Name: Biosidus S.A.U.
- Registered country: Argentina
- Address: Constitucion 4234, Buenos Aires
- Number of employees: 500 - 999
Description:
Biosidus is dedicated to the development, manufacturing and commercialization of high-quality recombinant proteins and biosimilars. Since launching erythropoietin in 1990, the company has introduced interferon alfa-2a, interferon alfa-2b, filgrastim, somatropin, lenograstim, azacitidine, bortezomib, interferon beta-1a (SC and IM) and teriparatide, expanding its portfolio in 2025 with the launch of agalsidase. Biosidus products are now commercialized in more than 50 markets worldwide.
Business Activities
Biopharmaceutical Products
Manufacturer
ATC (Anatomical Therapeutic Chemical) Classification
Manufacturer
Sales Markets
Key Products/Services
- ATC (Anatomical Therapeutic Chemical) Classification: Neutromax 30 M I.U./ 48 M I.U., Amilix/Bromadene, HHT 4 I.U/16 I.U. / HHT PEN 60 I.U., Blastoferon 22/44 mcg, Hemax 1.000/2.000/3.000/4.000/10.000/20.000/40.000 IU
- Innovator APIs: AZACITIDINE - AMILIX 100 MG, BORTEZOMIB - BROMADENE 3.5 MG, Agalzyme, SOMATROPIN - HHT Pen + AUTOINJECTOR DEVICE
Our Products & Services
Sell · ATC (Anatomical Therapeutic Chemical) Classification
Sell · ATC (Anatomical Therapeutic Chemical) Classification
Sell · ATC (Anatomical Therapeutic Chemical) Classification
Sell · ATC (Anatomical Therapeutic Chemical) Classification
Sell · ATC (Anatomical Therapeutic Chemical) Classification
Certifications
ISO
Proofs
CPHI Milan 2026
10/2026 – 10/2026
CPHI Milan 2026
Ratings
(0)
(0)
(0)
(0)
(0)
Comments
Filters:
Sort by:
No comments available.
Leave your rating & comment